APPB - Applied Biosciences Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2400
-0.0800 (-25.00%)
At close: 3:47PM EST
Stock chart is not supported by your current browser
Previous Close0.3200
Open0.2400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2400 - 0.2400
52 Week Range0.2000 - 2.2400
Volume9,000
Avg. Volume2,630
Market Cap3.251M
Beta (5Y Monthly)-0.22
PE Ratio (TTM)N/A
EPS (TTM)-0.2490
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Applied BioSciences' Subsidiary, Trace Analytics, Receives Extension of Contract of Services from Washington State Department of Agriculture

    Trace Analytics Inc. is a leading scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing WSDA contracted Trace Analytics for ...

  • Newsfile

    Applied BioSciences Outlines Key Value Driving Opportunities Expected in 2020 and Focus on Advancing BioPharma Pipeline with The Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - December 10, 2019) - The Stock Day Podcast welcomed Applied BioSciences Corp. (OTCQB: APPB) ("the Company"), a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. Applied's CEO, Dr. Raymond Urbanski, joined Stock Day host Everett Jolly, to discuss the Company's strategic focus on its BioPharma pipeline, its opportunity to ...

  • ACCESSWIRE

    Applied BioSciences Announces Strategic Shift to Fully Focus on BioPharma Division

    BioPharma division is focused on the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS) - BioPharma Division focus unlocks opportunities for non-dilutive ...

  • Newsfile

    Applied BioSciences Corp. Provides Corporate Update and Discusses Strategy for Focus on Building High-Value BioPharma Pipeline with the Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - November 19, 2019) - The Stock Day Podcast Host Everett Jolly welcomed Dr. Ray Urbanski, CEO of Applied BioSciences Corp. (OTCQB: APPB) ("the Company"), a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics/biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas.Dr. Urbanski provided a corporate overview and updated listeners on the current projects within the Applied ...

  • ACCESSWIRE

    Applied BioSciences Reports Second Quarter Fiscal Year 2020 Financial Results and Outlines Corporate Strategy

    The Company also provided an update on its corporate and clinical progress. The Company's growing pipeline is comprised of selective CB1 and CB2 agonist, inverse agonist and antagonists utilizing multiple scaffolds and state-of-the-art medicinal chemistry across several academic centers and institutions.

  • ACCESSWIRE

    Applied Products Signs Agreement to Sell Pond Naturals' Supplements Including its X10 Pet Supplements in the U.S.

    BEVERLY HILLS, CA / ACCESSWIRE / October 24, 2019 / Applied Products ("Applied" or the "Company"), a division of Applied BioSciences Corp. (APPB) and Pond Technologies Holdings Inc. ("Pond") (POND.V), announced today that Pond Naturals, Pond's wholly owned subsidiary, has entered a three-year license agreement with Applied Products to expand the distribution of its astaxanthin-based pet supplement to the U.S. As part of the agreement, Pond will sell its X10-branded pet products through Applied Products' established online sales channels. Applied BioSciences is focused on the development of science-driven biopharmaceuticals and the production of high-quality health and wellness products that target the endocannabinoid system. Through its Applied Products division, the Company currently develops multiple brands offering high quality health and wellness CBD products that conform to the highest regulatory standards and markets through established channels in the US, including its premium pet brand, Herbal Pet.

  • ACCESSWIRE

    Applied BioSciences Expands its Scientific Advisory Board for Applied BioPharma Division with Appointment of Patricia Reggio, Ph.D.

    BEVERLY HILLS, CA / ACCESSWIRE / October 10, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), today announced the appointment of Patricia Reggio, Ph.D., to its Scientific Advisory Board for the biopharma business unit of the Company, Applied BioPharma. Dr. Patricia Reggio is a well-established academic leader in cannabinoid research with over 30 years of experience.

  • ACCESSWIRE

    Applied BioSciences Appoints Michael Beaubaire, M.D. to its Board of Directors

    BEVERLY HILLS, CA / ACCESSWIRE / October 7, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), is a company focused on the development of science-driven biopharmaceuticals and the production of high-quality health & wellness products that target the endocannabinoid system, today announced the appointment of Michael Beaubaire, M.D., to its Board of Directors. Dr. Michael Beaubaire is a healthcare and finance leader with extensive experience in early stage drug development.

  • Newsfile

    The Stock Day Podcast Interviews CEO of Applied Biosciences to Discuss Near-Term Growth Expansion Strategy

    Phoenix, Arizona--(Newsfile Corp. - October 1, 2019) - The Stock Day Podcast welcomed Applied BioSciences Corp. (OTCQB: APPB) ("the Company") CEO, Raymond Urbanski, M.D. for an interview with Stock Day host, Everett Jolly. During the interview, Dr. Urbanski discussed the Company's progress with building a robust pipeline within its BioPharma division; the growth witnessed and further development of its marketing and eCommerce capabilities for the Company's Applied Products division; and the expected plans ...

  • ACCESSWIRE

    Applied BioSciences Appoints Judith Korner, M.D., Ph.D., as Inaugural Member of its Scientific Advisory Board for Applied BioPharma Division

    BEVERLY HILLS, CA / ACCESSWIRE / September 12, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today announced the appointment of Judith Korner, M.D., Ph.D., to its Scientific Advisory Board for the biopharma business unit of the Company, Applied BioPharma. “We are pleased to welcome Dr. Korner as a founding member of our Scientific Advisory Board.

  • ACCESSWIRE

    Applied BioSciences to Present at the Fall Investor Summit

    BEVERLY HILLS, CA / ACCESSWIRE / September 10, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today announced that Dr. Raymond Urbanski, Chief Executive Officer of Applied, will present at the Fall Investor Summit on Tuesday, September 17, 2019 at 10:00 AM ET in New York, NY. For more information about the conference, please click here to visit the conference website. A live audio webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company’s website.

  • ACCESSWIRE

    Applied BioSciences Subsidiary Enters into Contract for Services with Washington State Department of Agriculture

    BEVERLY HILLS, CA / ACCESSWIRE / August 27, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today announced that its majority owned subsidiary, Trace Analytics Inc., entered into a contract for services with the Washington State Department of Agriculture (WSDA) on July 24, 2019. This contract will include testing Industrial Hemp samples and include percentage testing for post-decarboxylation delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A).

  • ACCESSWIRE

    The Stock Day Podcast Interviews Newly Appointed CEO of Applied BioSciences to Discuss Strategy to Propel Company to Next Phase of Growth

    PHOENIX, AZ / ACCESSWIRE / August 1, 2019 / The Stock Day Podcast announced the launch of a recent interview with Applied BioSciences Corp. (APPB) (“the Company”), a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, as well as state-of-the-art testing and analytics capabilities to its customers. CEO of the Company, Dr. Raymond Urbanski, joined Stock Day host Everett Jolly to discuss recent corporate advancements and the Company’s vision to build a world-class biopharmaceutical company and execute on its strategic initiatives to propel the Company to its next phase of growth.

  • ACCESSWIRE

    Applied BioSciences Provides Corporate Update and 2019 Business Outlook

    BEVERLY HILLS, CA / ACCESSWIRE / July 30, 2019 / Applied BioSciences Corp. (APPB) ("Applied" or the "Company"), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today provided a corporate update and business outlook for the remainder of 2019.

  • Newsfile

    Applied BioSciences Announces Two Consecutive Quarters Posting Record Revenues for FY Ended March 2019

    Los Angeles, California--(Newsfile Corp. - July 24, 2019) - Applied BioSciences Corp. (OTCQB: APPB), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, as well as testing and analytics, and pet health industries, today announced that it has achieved a record revenue quarter with multiple milestones for the fiscal year ended March 31, 2019. The Company has continued to make strategic investments in ...

  • GlobeNewswire

    Applied BioSciences Launches Champ Organics CBD Product Line with Boxing Heavyweight Champion Shannon Briggs

    Applied Biosciences Corp. (OTC: APPB), a vertically integrated company focused on the development of science-driven cannabinoid therapeutics and biopharmaceuticals, announced that has officially launched its Champ Organics product line with Shannon “the Cannon” Briggs, the former heavyweight boxing champion and world record-holder for the most first-round knockouts. The product line was created to formulate a line of athlete-focused cannabidiol (“CBD”) based health and wellness supplements to enhance training and recovery under the “Champ Organics” brand. The initial product launch includes CBD Isolate Infused MCT Soft Gels and Tinctures, Full Spectrum CBD Oil Infused Topicals and Nano CBD Infused Natural Beverage Shots and Spring Water.

  • GlobeNewswire

    Applied Biosciences Hires Former Pfizer Business Unit Chief Medical Officer as Chief Executive Officer

    Dr. Urbanski, will work closely with the Board of Directors, will set the vision and strategic direction of the company putting into place the organizational structure, processes and key hires necessary to continue the growth of Applied BioSciences.  Dr. Urbanski will also oversee the development of key products in the Applied BioSciences’ product pipeline, including assets within the newly formed Applied BioPharma division which is focused on innovative cannabinoid therapies being developed to address the unmet medical needs of patients across multiple therapeutic areas. Dr. Urbanski joins Applied BioSciences with an impressive list of accomplishments throughout his career ranging from academic research and private practice to his work and rise within the pharmaceutical industry.  Dr. Urbanski spent eight years with Pfizer and held several positions within the company which included medical director of diversified products, senior medical director of breast cancer products, senior medical director of oncology clinical R&D, and eventually Vice President/Chief Medical Officer of the Established Products Business Unit.  In addition to his roles with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of MannKind Corp., and Senior Director of US Medical Affairs for Aventis.

  • ACCESSWIRE

    Uptick Newswire Hosts Applied Biosciences Corp. on The Stock Day Podcast to Discuss The Expansion of Their CBD Product Lines

    PHOENIX, AZ / ACCESSWIRE / April 18, 2019 / Uptick Newswire Stock Day Podcast welcomed Applied Biosciences Corp. (APPB) (''the Company''), a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. Treasurer and Secretary, JJ Southard, joined Stock Day host Everett Jolly. Jolly began the interview by asking Southard to give listeners an update on the Company's current projects.

  • ACCESSWIRE

    Applied BioSciences Retains the Emmes Group to Partner on Therapeutic Development Initiatives

    LOS ANGELES, CA / ACCESSWIRE / April 8, 2019 / Applied Biosciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical, testing and pet health industries, announced that is has retained the Emmes Group to assist with the development and execution of the Company's partnership and technology licensing initiatives and strategies. Through this new partnership, Emmes and the Company will work together to formulate a line of medical and scientific focused cannabidiol ("CBD") based products to target the endocannabinoid system under the "Applied BioPharma" brand. Applied BioSciences has retained several industry leading individuals as scientific advisory board members and in corporate management consultative capacities.

  • GlobeNewswire

    Applied BioSciences Announces Partnership with Boxing Heavyweight Champion Shannon Briggs

    Through this new partnership, Briggs and the Company will work together to formulate a line of athlete-focused cannabidiol (“CBD”) based health and wellness supplements to enhance training and recovery under the “Champ Organics” brand. Additionally, Briggs and the Company will collaborate on an awareness campaign to help educate athletes around the world about the potential benefits of using CBD for pain management, relaxation, decreasing anxiety and improving sleep quality.  Briggs hopes to educate the public on the potential benefits of using CBD to help decrease dependence on opioids. “I have partnered with Applied BioSciences to develop and market Champ Organics because their products are made with the highest quality ingredients and all-natural CBD.  I am a firm believer in the benefits that CBD delivers for joint pain and headaches.

  • GlobeNewswire

    Applied BioSciences Announces Record Revenue

    Applied BioSciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical, testing and analytics and pet health industries, announced that it has achieved a record revenue quarter with multiple milestones. The company has made strategic investments in select brands and companies believed to be innovators in the consumer space.  The investment remains on the balance sheet under Equity Investments, but the company has begun a strategic review of options for the remaining equity stake.

  • GlobeNewswire

    Applied BioSciences Receives Distribution from Investment in JUUL

    LOS ANGELES, Feb. 05, 2019 -- Applied BioSciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health.

  • GlobeNewswire

    Applied BioSciences Expands Scientific Advisory Board

    Applied BioSciences Corp. (APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced that Dr. Xiang-Qun (Sean) Xie has joined its Scientific Advisory Board. The company continues to add professionals who are expert in relevant fields, such as scientific research and development, FDA procedures and medicine.  These professionals will provide the company with an outstanding base of knowledge and experience to build on and advance the development of additional products.  With the addition of several prominent scientists and physicians and their knowledge base, clinical trials, product development, and design procedures for submitting products to the FDA can be done in an expedited time frame.